Welcome to our dedicated page for Biorestorative Therapies news (Ticker: BRTX), a resource for investors and traders seeking the latest updates and insights on Biorestorative Therapies stock.
BioRestorative Therapies, Inc. (NASDAQ: BRTX) is a regenerative medicine company focused on stem cell-based therapies and products, and its news flow reflects activity across clinical development, intellectual property, commercialization, and capital markets. The company develops therapeutic products using adult stem cell protocols, with core programs in disc and spine disease, metabolic disorders, and a commercial BioCosmeceutical platform.
News about BRTX often centers on its disc/spine program (brtxDISC™) and lead cell therapy candidate BRTX-100. Recent announcements include Fast Track designation from the U.S. Food and Drug Administration (FDA) for the BRTX-100 Phase 2 trial in chronic lumbar disc disease and the granting of a Type B meeting with the FDA to discuss a potential accelerated Biologics License Application approval pathway. Updates also cover blinded Phase 2 clinical data presented at scientific meetings and the status of enrollment and trial progress.
Another key news theme is the ThermoStem® metabolic program, where BioRestorative has reported milestones such as a Notice of Allowance from the Japanese Patent Office for its allogeneic, off-the-shelf brown adipose-derived stem cell technology designed to treat obesity and metabolic disorders. Press releases describe how this intellectual property strengthens protection for cell-based approaches that aim to generate brown adipose tissue and utilize exosomes secreted by brown adipose-derived stem cells.
Investors following BRTX news will also see coverage of the company’s BioCosmeceutical platform, including commercial developments for its cell-based secretome serum, as well as corporate events such as equity financings, stock repurchase authorizations, conference presentations, and quarterly financial results. This page aggregates these updates so readers can track BioRestorative’s clinical, commercial, and financial disclosures in one place.
BioRestorative Therapies, Inc. (BRTX), a clinical-stage company focused on stem cell therapies, has completed enrollment for the safety run-in of its Phase 2 clinical study of BRTX-100. This innovative treatment aims to address chronic lumbar disc disease (cLDD) by targeting areas with low blood flow. The study is randomized and double-blinded, involving up to 99 patients at 15 U.S. clinical sites. CEO Lance Alstodt highlighted the milestone, stating that positive safety results would enable broader enrollment and further development of BRTX-100 across other medical applications. The company aims to leverage this platform for expedited regulatory pathways. Initial clinical data is expected to be released in the second half of 2023.
BioRestorative Therapies (BRTX) has engaged Bruder Consulting & Venture Group to help expand the clinical indication pipeline for BRTX-100, its lead candidate targeting chronic lumbar disc disease (cLDD). Currently in a Phase 2 trial, BRTX-100 is a novel cell-based therapy aimed at areas with limited blood flow. The randomized, double-blinded trial involves 99 patients across 15 sites in the U.S. with a focus on safety and efficacy. BCVG's expertise in regulatory processes will support BioRestorative in obtaining FDA approval for new clinical applications of BRTX-100.
BioRestorative Therapies, Inc. (BRTX) announced its participation in the Roth 35th Annual Conference from March 12-14, 2023, at The Ritz Carlton, Laguna Niguel in Dana Point, California. CEO Lance Alstodt will be available for one-on-one meetings and provide updates on the company's pipeline, including the ongoing Phase 2 clinical trial for BRTX-100, targeting chronic lumbar disc disease. BioRestorative focuses on cell-based therapies, emphasizing its lead product for disc disorders and a metabolic program aimed at obesity. More information about the conference can be found on their official website.
BioRestorative Therapies (BRTX) announced a notice of allowance for a patent on its ThermoStem® program, which targets obesity and metabolic disorders, including type 2 diabetes. Issued on February 24, 2023, this marks the third patent in the ThermoStem family. The new patent covers implantable three-dimensional scaffolds and brown adipocytes derived from human stem cells. CEO Lance Alstodt stated this advancement strengthens the company's technology and opens doors for collaborations. BioRestorative also develops a disc/spine therapy using autologous stem cells.
BioRestorative Therapies (BRTX) announced a significant milestone with the European Patent Office issuing a notice of allowance for a patent related to its ThermoStem® program on February 6, 2023. This patent, which covers implantable three-dimensional scaffolds derived from human brown adipose stem cells, aims to treat obesity and metabolic disorders like type 2 diabetes. The technology combines scaffolds for cell delivery with brown adipose-derived stem cells, potentially benefiting multi-billion dollar markets.
CEO Lance Alstodt emphasized the importance of this patent in enhancing development capabilities in Europe, furthering their commitment to addressing metabolic disorders.
BioRestorative Therapies (BRTX) has received a Phase I SBIR grant from the NIH to advance its ThermoStem program aimed at treating Polycystic Ovary Syndrome (PCOS). This grant supports a partnership with Dr. Sheng Wu from Temple University, focusing on developing therapeutic brown adipocyte transplantation for PCOS patients, a condition affecting 6-18% of reproductive-age women. PCOS carries high annual healthcare costs of $4.36 billion in the US, highlighting the need for effective treatments.
BioRestorative Therapies, Inc. (NASDAQ: BRTX) announced an exclusive licensing agreement with Regenexx, LLC for technology addressing chronic lumbar disc disease. This intellectual property will enhance BRTX's lead program, BRTX-100, currently in Phase 2 trials across about 15 sites in the U.S. The CEO, Lance Alstodt, emphasized the importance of this milestone for creating non-invasive treatments aimed at the $40 billion spent annually on surgical procedures. The technology utilizes hypoxia to improve cell-based therapies' efficacy and safety.
MELVILLE, N.Y., Nov. 29, 2022 - BioRestorative Therapies, Inc. (BRTX) announces CEO Lance Alstodt's participation in the RHK Capital Disruptive Growth Conference in New York City on December 5-6, 2022. This event will gather executives from 30 disruptive companies and institutional investors, market analysts, and financial advisors. BioRestorative focuses on therapeutic products utilizing adult stem cells for treating spinal and metabolic disorders, featured in their core programs brtxDISC™ and ThermoStem®.
BioRestorative Therapies, Inc. (Nasdaq: BRTX) has announced its participation in the RHK Capital Disruptive Growth Conference scheduled for December 5-6, 2022, in New York City. Lance Alstodt, the company's President and CEO, will engage in one-on-one meetings to discuss the latest updates on the company's expanded pipeline and ongoing Phase 2 clinical trial targeting chronic lumbar disc disease. The trial utilizes the BRTX-100 cell therapy, which aims to provide non-surgical treatment for painful lumbosacral disc disorders.
BioRestorative Therapies (NASDAQ: BRTX) announced an upcoming interview with CEO Lance Alstodt on Famela and Friends Talk Radio, focusing on the company's clinical development pipeline. BioRestorative is currently conducting a Phase 2 trial for its lead therapy candidate, BRTX-100, aimed at treating chronic lumbar disc disease. The trial involves up to 99 patients across 15 U.S. centers, assessing safety and efficacy. The company also highlighted its Metabolic Program utilizing stem cells from brown adipose tissue.
FAQ
What is the current stock price of Biorestorative Therapies (BRTX)?
What is the market cap of Biorestorative Therapies (BRTX)?
